Last reviewed · How we verify
Primary Medical Treatment Pathway
This drug works by inhibiting the action of vascular endothelial growth factor (VEGF) to reduce angiogenesis.
This drug works by inhibiting the action of vascular endothelial growth factor (VEGF) to reduce angiogenesis. Used for Treatment of neovascular (wet) age-related macular degeneration, Treatment of macular edema following retinal vein occlusion.
At a glance
| Generic name | Primary Medical Treatment Pathway |
|---|---|
| Also known as | Conventional medical therapy; "Medicine First" |
| Sponsor | Moorfields Eye Hospital NHS Foundation Trust |
| Drug class | anti-VEGF agent |
| Target | VEGF |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
Mechanism of action
VEGF is a protein that promotes the formation of new blood vessels. By inhibiting VEGF, this drug reduces the growth of new blood vessels, which can help to slow the progression of certain eye diseases.
Approved indications
- Treatment of neovascular (wet) age-related macular degeneration
- Treatment of macular edema following retinal vein occlusion
Common side effects
- Intraocular inflammation
- Endophthalmitis
- Retinal detachment
Key clinical trials
- Telemedicine-Based Integrated Care for Heart Failure Prevention in Older Patients With Atrial Fibrillation (MIRACLE-AF III) (NA)
- Telemedicine-based Integrated Management of Atrial Fibrillation and Heart Failure in Older Patients in Village Clinics (NA)
- Study on the Prevention of Recidivism and the Consequences of Sexual Violence Suffered by Female Asylum Seekers in France
- Hyperkalemia Quality Improvement Program (HK-QIP) Study (NA)
- Single-Fraction Pulmonary Ablative Radiotherapy Outcomes and Quality-of-life Workup
- Clinical Study on an Artificial Intelligence-Assisted Chest Radiograph Model Based on Big Data and Deep Learning for Early Detection of Kawasaki Disease
- Stratified Targeted Engagement From Primary Care to Physical Therapy (STEPPT) (NA)
- Smartwatch-based Intervention for Cardiovascular Health (SWITCH) (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: